| Metric | Q4 FY26 | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue from operations | 1864.4 | 1806.1 | 1509.6 |
| Other income | 20.6 | 18.2 | 15.8 |
| Total income | 1885.0 | 1824.4 | 1525.4 |
| Profit before exceptional items & tax | 80.3 | 73.3 | 61.1 |
| Profit before tax | 80.3 | 73.3 | 61.1 |
| Net profit | 64.0 | 57.8 | 51.3 |
| Operating margin | 4.3% | 4.0% | 4.0% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +24.80% |
|---|---|
| Net profit, quarter on quarter | +10.70% |
| Revenue, year on year | +23.50% |
NSE results filing, NSE: MEDPLUS. Figures extracted from the filing.
Medplus Health Services Ltd: key numbers
- Share price
- ₹654.90
- Market cap
- ₹7,868 Cr
- Revenue (annual)
- ₹6,892 Cr
- Net profit (annual)
- ₹219.7 Cr
- P/E (TTM)
- 37.4×Sector 57.8×
- Promoter holding
- 40.19%-0.03% QoQ
- FII holding
- 14.38%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Medplus Health Services Ltd
All →Medplus Health Services Adverse Business Impact
Medplus Health Services' subsidiary, Optival Health Solutions, faced a three-day drug license suspension at a store by the Drugs Control Administration, impacting operations by ₹0.01 Crore.
- Value
- ₹0.01 Cr
- From
- Drugs Control Administration, Haveri Circle, Karnataka
Medplus Health Services Legal & Regulatory
MedPlus Health Services' subsidiary, Optival Health Solutions, received a one-day drug license suspension from the Drugs Control Administration for a store in Telangana due to non-compliance.
- Value
- ₹0.01 Cr
Medplus Health Services Legal & Regulatory
Medplus Health Services' subsidiary, Optival Health, received a 7-day drug license suspension in Andhra Pradesh and stay orders for previous suspensions in Maharashtra.
- Value
- ₹0.02 Cr
Medplus Health Services Legal & Regulatory
Medplus Health Services disclosed that regulatory authorities suspended the drug licenses of five subsidiary stores for 3 to 7 days. The expected financial impact is ₹0.10 Crore.
- Value
- ₹0.10 Cr
Medplus Health Services Adverse Business Impact
Medplus Health Services reported a 7-day drug license suspension for a subsidiary store, impacting its operations with an estimated financial loss of ₹0.02 Crore.
- Value
- ₹0.02 Cr
- Execution
- 7 days
Medplus Health Services Adverse Business Impact
Medplus Health Services' subsidiary, Optival Health Solutions, faced drug license suspensions for two stores from regulatory authorities, causing a total financial impact of Rs 0.0961 Crore.
- Value
- ₹0.10 Cr
- Execution
- 5 to 15 days